WBI Investments LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

WBI Investments LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 29,146 shares of the biopharmaceutical company’s stock after purchasing an additional 9,731 shares during the period. WBI Investments LLC’s holdings in Gilead Sciences were worth $2,692,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HHM Wealth Advisors LLC raised its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter worth about $28,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the fourth quarter worth $31,000. Stephens Consulting LLC raised its position in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 25,429 shares of company stock worth $2,894,445. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 25th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Trading Up 2.2%

Gilead Sciences stock opened at $102.50 on Monday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company’s fifty day moving average price is $105.75 and its two-hundred day moving average price is $99.84. The company has a market capitalization of $127.50 billion, a price-to-earnings ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.32) earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.08%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.